PAT crashed 54% YoY; core business flattening masks subsidiary bleeding

PAT -54% YoY; revenue +3.8% vs prior 10% run-rate; OPM 13.2%, NPM 3.4%

NPM 3.4% (very thin); PAT crashed despite COGS 2% improvement standalone

Management vague on Q1 actual; no P&L breakdown provided; ₹20 Cr unverified

Machine reliability still below standard; moved from terrible to poor; no revenue traction claimed

Admitted external headwinds (Iran, extrusion cyclicality); delayed Assam capex 6+ months

Previously guided FY27 breakeven; now H1 FY28. Shiva admitted 'moving from terrible to poor' on V-Shapes; machine issues unresolved.

Standalone revenue +5% (₹100→105 Cr), consolidated +3.6%. Lagged prior run-rate; blamed extrusion/Iran but no quantified recovery timeline.

Mentioned 'couple of price increases' but insufficient to offset sticky supplier cost increases; margins remain under pressure.

July 1, 2026 referenced but no enforcement; implementation timeline 2-phase, start FY28. Market expansion IF regulation passes.

Demand real; execution issue (machine consistency, operator learning curve). Fixing 95/100 packet reliability; past sales didn't perform. Pivot to co-packaging and internal use.

Core steady, 10–15% growth expected by FY27-end. Margin unchanged except FX. Suppliers exploiting stickiness; modest price increases taken. Careful on timing, not on maximizing short-term sales.

Opportunity is big; not pulling plug now. Demand exists, we just need to execute. If no path forward, will take tough call, but issue is performance not opportunity.

Running pilots; each customer has own cycle (IQ, DQ, PQ); 1.5–2 year gestation. Already ₹20 Cr last FY at breakeven. Q3 will show progress.

Iran uncertainty, polymer prices, extrusion cyclical. Q4 is typical strength; Q1 always slower. Expect catch-up in remaining 3 quarters.

574 printers Q1. [Did not compare to prior quarters.] Consumables delayed due to extrusion slowdown; expect recovery.

Margins unchanged except FX and slight consumables dip in Q1. Expect same trend for rest of year. Q2, Q3, Q4 on positive trend.

TAM ₹500–600 Cr. We captured ₹20 Cr last FY (~3% share). Two growth levers: unique propositions (market expansion + share) + government SKU expansion (300→1,000 brands, ₹600→₹1,500 Cr TAM).

Government suspended new unit registrations under scheme. In limbo; waiting for government notice. Equipment ordered, ready, but no timeline.

Packaging as whole likely H1 FY28, not H2 FY27. Will update Q2. UNNATI was planned for both C&M and Packaging but now in limbo.

Saw some revenue growth across both; some machine orders delayed per customer request. Servicing from own Packaging facilities.

June back to normal. Volatility, not absolute price, is the issue. Raw material cost for co-packaging spiked; customer margins thin. Extrusion customer conservatism high.

Problem NOT solved. QR codes still copyable; batch counterfeiting real. Our solution aims to address but is unproven. Problem 'still very much true.'

QRiousCodes breakeven/profitable; no exit. International breakeven expected; no exit. Packaging: demand real, we're just not performing. Won't exit if path exists; will take tough call if no path.

Still in discussion; not enforced. 2-phase implementation over 2 years. Industry lobbying against. Won't happen by July 2026. Let's see final outcome.

Q1 +3–5%; management expects catch-up in Q2–Q4 due to Q4 seasonality and extrusion recovery. Iran, polymer price volatility cited.

Breakeven pushed to H1 FY28 (deferred from FY27). Co-packaging pipeline expanding but machine issues unresolved.

Still in discussion paper; no enforcement timeline. Phased 2-year rollout if approved. Company claims ₹20 Cr current base, only 3% share.

Currently near those levels but only if you exclude other business investments. Consolidated margin much lower due to subsidiary drag.

Q1 OPM 13.2%. Unlikely to improve with V-Shapes still bleeding. Cost increases cited as 'sticky' and hard to pass through.

Government scheme suspended. Equipment ordered, registration ready. No restart date. Was planned for co-packaging + C&M; expected ₹100+ Cr capacity.

V-Shapes bleeding; ₹65 Cr invested with marginal traction. Machine reliability still 95/100 (unacceptable for customers). Breakeven pushed to FY28 H1.

Standalone Coding & Marking +5% Q1 (vs typical 10%+ run-rate). Management attributes to extrusion/Iran but no structural fix communicated. Price increases only 'couple' despite sticky costs.

Track & Trace TAM ₹600 Cr; CPL only ₹20 Cr (~3% share). Pharma pilots underway but 1.5–2 year gestation. Government QR mandate expansion still in discussion paper; no enforcement timeline; industry lobbying risk.

Assam UNNATI facility in limbo; government suspended new unit registrations. Co-packaging / laminates capacity expansion on hold. Expected revenue impact not quantified.

PAT -54% YoY (₹3.9 Cr) but management claimed 'no major changes' to PBT. Consolidated profit drivers not broken out. Implies subsidiary losses masked by claim of stable core.